{"id":7067,"date":"2026-10-22T11:34:33","date_gmt":"2026-10-22T06:04:33","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-22\/"},"modified":"2026-10-22T20:31:01","modified_gmt":"2026-10-22T15:01:01","slug":"drreddy-share-price-today-2026-10-22","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-22\/","title":{"rendered":"Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Falling 0.44% | 22 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: DRREDDY<\/strong> \u00b7 22 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,239.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-0.44%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,250.70 \/ \u20b91,212.70<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,244.50<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>28.05 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>22 October 2026 \u00b7 03:30 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Dr. Reddy&#x27;s Laboratories shares edged lower during the session, trading down by 0.44% to close at \u20b91,239.00 compared to its previous close of \u20b91,244.50. The stock moved within a daily range of \u20b91,212.70 and \u20b91,250.70 after opening slightly lower at \u20b91,236.00.<\/li>\n<li>The United States Food and Drug Administration completed a pre-approval inspection at the company&#x27;s FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated it will address these observations within the stipulated timeline.<\/li>\n<li>Trading volume was 1.29 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Dr. Reddy S Laboratories share price falling on 22 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Dr. Reddy&#x27;s Laboratories shares edged lower during the session, trading down by 0.44% to close at \u20b91,239.00 compared to its previous close of \u20b91,244.50. The stock moved within a daily range of \u20b91,212.70 and \u20b91,250.70 after opening slightly lower at \u20b91,236.00.<\/p>\n<p class=\"wt-copy\">In broader market context, the stock&#x27;s minor pullback occurred alongside a sharper decline in the benchmark Nifty index, which fell 0.88%, while the sectoral Nifty Pharma index remained relatively resilient with a minor loss of 0.07%. Over the preceding trading days, the stock had posted gains of 0.16% and 0.93% over the prior two sessions, and a 5-day return of 1.89%, indicating the day&#x27;s move followed a period of modest short-term strength.<\/p>\n<p class=\"wt-copy\">Company-specific news flow includes the recent regulatory update from October 21, 2026, where the company announced that the DCGI approved Zytorvi (toripalimab) for advanced esophageal squamous cell carcinoma in India. Additionally, investors are monitoring upcoming quarterly financial results scheduled for release on October 23, 2026, though no single catalyst was directly linked to today&#x27;s minor price adjustment.<\/p>\n<p class=\"wt-copy\">28.05 lakh shares traded by 22 October 2026 \u00b7 03:30 PM IST. This compares with a 20-day average daily volume of 21.67 lakh shares (1.29 times). The five-day average daily volume was 13.03 lakh shares. Separately, the NSE report for 22 October 2026 showed 14.89 lakh shares delivered, representing 53.08% of that day\u2019s traded volume. The same report recorded 59,886 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>profit-taking after recent strength and broader market softness<\/strong><\/p>\n<p class=\"wt-copy\">The 0.44% decline appears consistent with minor profit-taking following recent positive short-term returns, occurring alongside a broader market dip led by the Nifty index while trading volume remained active above average levels.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">USFDA Pre-Approval Inspection at Visakhapatnam Facility<\/div>\n<div class=\"wt-card-date\">14 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The United States Food and Drug Administration completed a pre-approval inspection at the company&#x27;s FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated it will address these observations within the stipulated timeline.<\/p>\n<p class=\"wt-copy\">Timely resolution of regulatory observations is crucial for securing final product approvals tied to this manufacturing unit.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Upcoming Q2 FY27 Financial Results Schedule<\/div>\n<div class=\"wt-card-date\">7 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company formally notified the stock exchanges that it will convene a board meeting to approve its standalone and consolidated financial results for the quarter and six months ended September 30, 2026. An earnings call with management is scheduled for October 23, 2026, at 19:30 PM IST to discuss the operational performance.<\/p>\n<p class=\"wt-copy\">Provides investors with the official timeline to assess quarterly revenue growth, profit margins, and segment performance against expectations.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_07102026144117_SE_Intimation_Earning_call_Notification_07102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">21 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 21, 2026, titled &quot;Dr. Reddy s Receives DCGI Approval for Zytorvi\u00ae (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_21102026094355_DRL_SE_intimation_Press_release_21102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">7 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 07, 2026, titled &quot;Intimation of Earnings call&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_07102026144117_SE_Intimation_Earning_call_Notification_07102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Order \/ business win<\/div>\n<div class=\"wt-card-date\">3 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_03102026171508_SE_intimation_03102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">26.63%<\/div>\n<div class=\"wt-note\">26.64% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">31.39%<\/div>\n<div class=\"wt-note\">32.07% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">63.27%<\/div>\n<div class=\"wt-note\">63.81% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742881_21102026034106_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Patrick Aghanian<\/strong><span class=\"wt-note\">Insider \/ disclosed person<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>3,675 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>26 March 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Tricia Wetzel<\/strong><span class=\"wt-note\">Insider \/ disclosed person<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>4,275 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>9 December 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 14.14% on 30 September 2026. This compares with 13.16% on 30 June 2026, a change of +0.98 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 40 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ISIF EQUITY EX-TOP 100 LONG-SHORT FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">4.81 crore shares \u00b7 5.76%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">NIPPON LIFE INDIA TRUSTEE LTD-A\/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.32 crore shares \u00b7 1.58%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">PARAG PARIKH FLEXI CAP FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.22 crore shares \u00b7 1.46%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742881_21102026034106_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Release of Q2 FY27 financial results and management commentary on October 23, 2026<\/li>\n<li>Updates on the regulatory response to the USFDA Form 483 observations at the Visakhapatnam facility<\/li>\n<li>Commercial progress and market uptake following the recent DCGI approval of Zytorvi in India<\/li>\n<li>Delivery volume trends and cash market participation relative to the 20-day average volume<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-21\/\">Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 0.22% | 21 October 2026 \u2014 21 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-15\/\">Dr. Reddy&#x27;s Laboratories in Focus After USFDA Issues Form 483 | 15 October 2026 \u2014 15 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-13\/\">Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 2.71% | 13 October 2026 \u2014 13 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/drreddy\/\">More Dr. Reddy S Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Dr. Reddy S Laboratories company news?<\/h3>\n<p class=\"wt-copy\">The United States Food and Drug Administration completed a pre-approval inspection at the company&#x27;s FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, between October 8 and October 9, 2026. The inspection resulted in the issuance of a Form 483 containing three observations. The company stated it will address these observations within the stipulated timeline.<\/p>\n<h3>How strong was Dr. Reddy S Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">28.05 lakh shares traded, 1.29 times the 20-day average daily volume. The price and volume data are dated 22 October 2026 \u00b7 03:30 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-22\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-22\/\"}, \"headline\": \"Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Falling 0.44% | 22 October 2026\", \"description\": \"Dr. Reddy S Laboratories share price fell 0.44% to \u20b91,239.00 today. See why DRREDDY is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-22T06:04:33Z\", \"dateModified\": \"2026-10-22T20:30:52.131293+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/drreddy-company-news-2026-10-22.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 21, 2026, titled \\\"Dr. Reddy s Receives DCGI Approval for Zytorvi\u00ae (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.\\\".\",\"source\":\"NSE\",\"published\":\"21-Oct-2026 09:44:09\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_21102026094355_DRL_SE_intimation_Press_release_21102026_signed.pdf\",\"disclosure_text\":\"October 21, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir\/Madam, Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed a Press Release viz. \u201cDr. Reddy\u2019s Receives DCGI Approval for Zytorvi\u00ae (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India\u201d This is for your information and records. Thanking you, Yours faithfully, For Dr. Reddy\u2019s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad \u2013 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com Press Release CONTACT INVESTOR RELATIONS MEDIA RELATIONS AISHWARYA SITHARAM AISHWARYASITHARAM@DRREDDYS.COM SANTOSH VYAS SANTOSHVYAS@DRREDDYS.COM Dr. Reddy\u2019s Receives DCGI Approval for Zytorvi\u00ae (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India The approval expands the use of Zytorvi\u00ae beyond its initially approved indication in nasopharyngeal carcinoma (NPC) Hyderabad, India; October 21, 2026: Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as \u201cDr. Reddy\u2019s,\u201d) today announced that the Central Drugs Standard Control Organisation (CDSCO), under the Drugs Controller General of India (DCGI), has approved Zytorvi\u00ae (toripalimab) in combination with cisplatin and paclitaxel for the first -line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).1 Dr. Reddy\u2019s entered into a licensing and commercialization agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries . Globally, Toripalimab is approved by regulatory authorities including the U.S. Food and Drug Administration (USFDA), the European Medicines Agency ( EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).2 Notably, the EMA approval is for first-line treatment of ESCC irrespective of PD-L1 expression.3 The approved indication in India similarly does not require patient selection based on PD-L1 expression, enabling appropriate patients to be considered for treatment regardless of their biomarker status.1,3 In 2024, esophageal cancer was the fourth leading cause of cancer -related death in India , accounting for approximately 8.1% of all cancer deaths 4. ESCC, the predominant subtype, accounts for approximately 80% of all esophageal cancer cases in India. Through Zytorvi\u00ae, Dr. Reddy\u2019s Laboratories Ltd. aims to expand access to first-line immunotherapy for appropriate patients with advanced ESCC in India. The approval is supported by the results from the Phase 3 JUPITER-06 trial. In the study, toripalimab in combination with paclitaxel and cisplatin reduced the risk of disease or death by 42% compared with chemotherapy alone. 7 At the final overall -survival analysis, median overall survival was 17.7 months with toripalimab plus chemotherapy compared with 12.9 months with chemotherapy alone . Clinical benefit was observed across PD-L1-expression subgroups.8 M.V. Ramana, Chief Executive Officer, Global Generics, Dr. Reddy\u2019s Laboratories, said: \u201cFollowing the approval of Zytorvi\u00ae in nasopharyngeal carcinoma, this second indication marks an important step in extending the reach of immunotherapy to patients with advanced esophageal squamous cell carcinoma. It gives physicians an additional first -line treatment option for appropriate patients. As we continue to build our oncology portfolio, our focus remains on bringing meaningful advances and expanding access to innovative treatment options.\u201d About esophageal squamous cell carcinoma Esophageal cancer begins in the tissues of the esophagus, the muscular tube that carries food and liquids from the throat to the stomach. ESCC develops from the squamous cells lining the esophagus. Risk factors associated with ESCC include smoked and smokeless tobacco, alcohol consumption, areca -nut use, consumption of very hot beverages, poor diet and certain environmental and socioeconomic factors. Risk Press Release Page 2 varies between individuals, and the presence of one or more risk factors does not mean that a person will necessarily develop cancer. Progressive difficulty in swallowing, pain or discomfort when swallowing, unexplained weight loss, persistent chest discomfort and regurgitation may be associated with esophageal cancer. These symptoms may also be caused by other conditions and require evaluation by a qualified healthcare professional.5,6 About Zytorvi\u00ae (toripalimab) Zytorvi\u00ae contains toripalimab, a next -generation humanised IgG4 monoclonal antibody 9 directed against programmed death receptor -1, or PD-1. By binding to PD -1, toripalimab blocks its interaction with PD -L1 and PD-L2, supporting T-cell activity against cancer cells.3 In 2023, Dr. Reddy\u2019s entered into a licence and commercialisation agreement with Shanghai Junshi Biosciences Co., Ltd. for toripalimab. Under this agreement, Dr. Reddy\u2019s holds exclusive rights to develop and commercialise toripalimab in 21 countries, including India, South Africa, Brazil and several countries in Latin America, Australia, New Zealand and nine other countries.2 Dr. Reddy\u2019s launched Zytorvi\u00ae in India in November 2024 for recurrent or metastatic nasopharyngeal carcinoma, making India the third country in the world, after China and the United States, to receive access to the medicine.2 Toripalimab is approved by regulatory authorities including the U.S. Food and Drug Administration (USFDA), the EMA and the UK Medicines and Healthcare products Regulatory Agency (MHRA). 2 The European Commission authorised toripalimab for first-line ESCC in September 2024.3 \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 About Dr. Reddy\u2019s : Dr. Reddy\u2019s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of \u2018Good Health Can\u2019t Wait\u2019, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, d iabetology, oncology, pain management and dermatology. Our major markets include \u2013 USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026 Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management\u2019s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward- looking by reason of context, the words \\\"may\\\", \\\"will\\\", \\\"should\\\", \\\"expects\\\", \\\"plans\\\", \\\"intends\\\", \\\"anticipates\\\", \\\"believes\\\", \\\"estimates\\\", \\\"predicts\\\", \\\"potential\\\", or \\\"continue\\\" and similar expressions identify forward -looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency \/ severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and\/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers\u2019, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the \\\"Risk Factors\\\" and \\\"Forward-Looking Statements\\\" sections of our Annual Report on Form 20-F for the year ended March 31, 2026. The company assumes no obligation to update any information contained herein. References 1. CDSCO approval letter, Letter No. BIO\/IMP\/25\/000057, dated 24th September 2026, approving Toripalimab for the treatment of Advanced Esophageal Squamous Cell Carcinoma. Data on file, Dr Reddy\u2019s Laboratories Ltd. 2. Dr. Reddy\u2019s Laboratories Ltd. Dr. Reddy\u2019s launches toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma [press release on the Internet]. Hyderabad: Dr. Reddy\u2019s Laboratories Ltd; 2024 Nov 28 [cited 2026 Oct 5]. Available from: https:\/\/www.drreddys.com\/cms\/cms\/sites\/default\/files\/2024- 11\/Dr.%20Reddy%27s%20press%20release%20-%20launch%20of%20Toripalimab%20in%20India.pdf 3. European Medicines Agency. Loqtorzi: European public assessment report [Internet]. Amsterdam: European Medicines Agency; 2024 [cited 2026 Oct 5]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/loqtorzi 4. International Agency for Research on Cancer. Global Cancer Observatory: GLOBOCAN 2024 India fact sheet [Internet]. Lyon: International Agency for Research on Cancer; 2026 [cited 2026 Oct 5]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/356-india-fact-sheet.pdf 5. Choksi D, Kolhe KM, Ingle M, Rathi C, Khairnar H, Chauhan SG, et al. Esophageal carcinoma: an epidemiological analysis and study of the time trends over the last 20 years from a single center in India. J Family Med Prim Care. 2020;9(3):1695-9. doi:10.4103\/jfmpc.jfmpc_1111_19Ghosh B, Mathew A, Mullapally SK. Immunotherapy for cancer in India: navigating the access- efficacy chasm. Indian J Med Paediatr Oncol. 2026;47(4):323-5. doi:10.1055\/s-0046-1824566. Press Release Page 3 6. Noronha V, Sekar A, Rajendra A, Mokal S, Patil V, Menon N, et al. Epidemiological trend of esophageal cancer at a tertiary cancer center in Mumbai, India, over the past 15 years. J Gastrointest Cancer. 2023;54:903-12. doi:10.1007\/s12029-022-00887-z. 7. Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multicenter phase 3 trial. Cancer Cell. 2022;40(3):277-88.e3. doi:10.1016\/j.ccell.2022.02.007. 8. Chen YX, Jin Y, Chen YK, Cui C, Yao J, Zhang Y, et al. Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma. Ann Oncol. 2026;37(7):986-98. 9. Ravindranathan S, Wang X, Chin DJ, Tseng SY, Klakamp S, Widmann K, et al. Characteristics of toripalimab: a next-generation anti-PD-1 antibody with potent T-cell activation and enhanced clinical efficacy irrespective of PD-L1 status. J Immunother Cancer. 2023;11(Suppl 1):A522.\"},{\"summary\":\"a press release dated October 07, 2026, titled \\\"Intimation of Earnings call\\\".\",\"category\":\"Press Release\",\"date\":\"07-Oct-2026 14:41:26\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_07102026144117_SE_Intimation_Earning_call_Notification_07102026_signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.\",\"category\":\"Action(s) taken or orders passed\",\"date\":\"03-Oct-2026 17:15:38\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_03102026171508_SE_intimation_03102026_signed.pdf\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.\",\"category\":\"News Verification\",\"date\":\"18-Sep-2026 08:46:20\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_18092026084516_SE_intimation_18092026_NSE_signed.pdf\",\"headline\":\"Exchange clarification on media report\",\"impact\":\"This can influence near-term sentiment while investors wait for the company's response, but it becomes materially important only if the company confirms a financial or operational impact.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"Dr. Reddy's Laboratories Limited has today, i.e., September 18, 2026, entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga\u00ae in the private market in India.\",\"category\":\"Arrangements for strategic, technical, manufacturing, or marketing tie up\",\"date\":\"18-Sep-2026 09:04:41\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_18092026090427_DRL_SE_intimation_18092026_signed.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":4}],\"recent_news\":[{\"summary\":\"a press release dated October 07, 2026, titled \\\"Intimation of Earnings call\\\".\",\"category\":\"Press Release\",\"date\":\"07-Oct-2026 14:41:26\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_07102026144117_SE_Intimation_Earning_call_Notification_07102026_signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.\",\"category\":\"Action(s) taken or orders passed\",\"date\":\"03-Oct-2026 17:15:38\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_03102026171508_SE_intimation_03102026_signed.pdf\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.\",\"category\":\"News Verification\",\"date\":\"18-Sep-2026 08:46:20\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_18092026084516_SE_intimation_18092026_NSE_signed.pdf\",\"headline\":\"Exchange clarification on media report\",\"impact\":\"This can influence near-term sentiment while investors wait for the company's response, but it becomes materially important only if the company confirms a financial or operational impact.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"Dr. Reddy's Laboratories Limited has today, i.e., September 18, 2026, entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga\u00ae in the private market in India.\",\"category\":\"Arrangements for strategic, technical, manufacturing, or marketing tie up\",\"date\":\"18-Sep-2026 09:04:41\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_18092026090427_DRL_SE_intimation_18092026_signed.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"Patrick Aghanian\",\"category\":\"Insider \/ disclosed person\",\"type\":\"Buy\",\"quantity\":\"3675\",\"post_holding\":\"8450\",\"date\":\"26-Mar-2026\",\"mode\":\"ESOP\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Tricia Wetzel\",\"category\":\"Insider \/ disclosed person\",\"type\":\"Buy\",\"quantity\":\"4275\",\"post_holding\":\"4275\",\"date\":\"09-Dec-2025\",\"mode\":\"ESOP\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":26.63,\"public_pct\":73.17,\"fii_pct\":31.39,\"dii_pct\":31.88,\"mf_pct\":14.14,\"institutional_pct\":63.27,\"noninst_pct\":9.9,\"mf_scheme_count\":40,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"ISIF EQUITY EX-TOP 100 LONG-SHORT FUND\",\"shares\":48096919,\"pct\":5.76},{\"name\":\"NIPPON LIFE INDIA TRUSTEE LTD-A\/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND\",\"shares\":13225035,\"pct\":1.58},{\"name\":\"PARAG PARIKH FLEXI CAP FUND\",\"shares\":12225152,\"pct\":1.46},{\"name\":\"SBI NIFTY INDEX FUND\",\"shares\":10124803,\"pct\":1.21}],\"period\":\"30-SEP-2026\",\"submission_date\":\"21-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1742881_21102026034106_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":26.64,\"previous_fii_pct\":32.07,\"previous_dii_pct\":31.74,\"previous_mf_pct\":13.16,\"previous_institutional_pct\":63.81,\"previous_mf_scheme_count\":40,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Reddy S Laboratories share price fell 0.44% to \u20b91,239.00 today. See why DRREDDY is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":7066,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Falling 0.44% | 22 October 2026","_witty_meta_description":"Dr. Reddy S Laboratories share price fell 0.44% to \u20b91,239.00 today. See why DRREDDY is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"Dr. Reddy S Laboratories share price today","_witty_reason_label":"profit-taking after recent strength and broader market softness","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[87],"class_list":["post-7067","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-drreddy"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=7067"}],"version-history":[{"count":4,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7067\/revisions"}],"predecessor-version":[{"id":7480,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7067\/revisions\/7480"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/7066"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=7067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=7067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=7067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}